PGEN250117C2000
- 0.00
- 0.000.00%
Precigen Newsroom
JMP Securities Maintains Precigen(PGEN.US) With Buy Rating, Cuts Target Price to $5
Analysts Are Bullish on Top Healthcare Stocks: Precigen (PGEN), Vor Biopharma (VOR)
Precigen Launches $79 Million Private Placement
Express News | Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock
Press Release: Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock
Express News | Precigen : Received Cash Payment of $8.5 Mln at Closing of Asset Sale, Which Occurred on Dec 24
Express News | Precigen: Agreed to Sell to Innovator 21 LLC Certain Assets, Including Intellectual Property Rights and Royalty Rights, Related to Fcx-007
Express News | Precigen : On Dec 18, Entered Into Asset Acquisition Agreement With Innovator 21, LLC
Precigen Reports Q3 2024 Financial Results
Precigen (NASDAQ:PGEN Shareholders Incur Further Losses as Stock Declines 13% This Week, Taking Five-year Losses to 86%
Stifel Maintains Precigen(PGEN.US) With Buy Rating, Maintains Target Price $7
Precigen Price Target Maintained With a $4.00/Share by HC Wainwright & Co.
Precigen Analyst Ratings
H.C. Wainwright Maintains Precigen(PGEN.US) With Buy Rating, Maintains Target Price $4
JMP Securities Maintains Precigen(PGEN.US) With Buy Rating, Maintains Target Price $7
Precigen's Strategic Advancements and FDA Alignment Bolster Buy Rating
Precigen | 10-Q: Q3 2024 Earnings Report
Precigen GAAP EPS of -$0.09 Misses by $0.01, Revenue of $0.95M Misses by $0.33M
Precigen | 8-K: Precigen Reports Third Quarter 2024 Financial Results and Business Updates
Express News | Precigen Reports Third Quarter 2024 Financial Results and Business Updates